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  Orthopaedic surgery as a speciality lends itself well to 
tissue engineering. Many musculoskeletal tissues are 
frequently damaged or lost in injury and disease, and show a 
limited capacity for repair. Although orthopaedic surgery has 
been successful in replacing cartilage, the coming years will 
establish whether a shift from replacement towards 
regeneration of tissue is feasible. There has been an 
increasing interest in tissue engineering approaches to deal 
with damaged or lost tissue [1-3]. Tissue engineering is an 
exciting strategy that employs stem cells, scaffolds and 
growth factors or mediators either in isolation or in 
combination. It is the expanding science of generating tissue 
using molecular and cellular techniques, combined with 
material engineering principles, to replace tissue surgically. 
This could be in the form of cells with or without matrices. 
Many tissue engineering advances are being made in 
orthopaedics and this is partly due to the familiarity with 
bone marrow derived mesenchymal stem cells. In this review 
we will cover mesenchymal stem cells, scaffolds, bioreactors 
and growth factors applicable to orthopaedics and 
musculoskeletal sciences. This is followed by specific 
discussions on Dupuytren’s disease where there is early 
evidence of stem cell etiology, and bone and cartilage tissue 
engineering. 
STEM CELLS 
  Stem cells are a self-renewing cell population with a high 
proliferation potential and the ability to undergo 
chondrogenic, osteogenic and adipogenic differentiation. 
Protocols for the culture and differentiation of bone marrow 
derived mesenchymal stem cells have been described [4-6]. 
Over the last decade, there has been considerable interest in 
the use of mesenchymal stem cells and tissue engineering 
principles in orthopaedics and musculoskeletal sciences. The 
use of autologous postnatal mesenchymal stem cells is   
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generally well accepted by society and does not involve 
many of the ethical, political and religious considerations 
that surround embryonic stem cells [7]. Cells with 
mesenchymal stem cell characteristics have been isolated 
from many different adult tissues including bone marrow, 
periosteum, skin, adipose tissue, skeletal muscle, synovial 
tissue, the infrapatellar fat pad, and more recently, cartilage 
[8-15], and we provide a systematic review of the literature 
outlining the sources of mesenchymal stem cell used in 
musculoskeletal applications. 
  Human bone marrow-derived mesenchymal stem cells 
exhibit age-related changes; with increasing age, they are 
fewer in number [16, 17], have reduced proliferation [18] 
and reduced differentiation potential [19]. There is 
uncertainty whether these age-related changes are also 
exhibited by mesenchymal stem cells from other sources, 
and what the extent of these changes is in these other 
sources. There is a need to determine not only the effects of 
patient age on mesenchymal stem cells [20] but also the 
effect of senescence. There are many known growth factors 
involved in controlling and influencing stem cell growth that 
are also related to cell senescence, and we review these in 
vitro considerations. 
  Work by others and by us has shown that mesenchymal 
stem cells from the synovial fat pad are easier to obtain and 
are associated with a higher yield of mesenchymal stem cells 
compared to bone marrow [11, 21, 22]. Although 
mesenchymal stem cells from different tissues vary in their 
differentiation potential [23,24], it is possible that there are 
more similarities between stem cells from various sources 
than differences; increasing data supports pericytes as 
candidate mesenchymal stem cells in a number of sources 
[22,25]. These cells are identified using cell surface markers 
but there are no papers in the literature that bring together 
and summarize these cell surface markers. We present a 
systematic review that summarizes all the available 
information about the cell surface characterization of adult 
human MSCs by identifying and evaluating all the published 
literature in this field. We have found that the most 
commonly reported positive markers are CD105, CD90, 
CD44, CD73, CD29, CD13, CD34, CD146, CD106, CD54 
and CD166, and the most frequently reported negative 240    The Open Orthopaedics Journal, 2011, Volume 5  Editorial 
markers are CD34, CD14, CD45, CD11b, CD49d, CD106, 
CD10 and CD31. 
SCAFFOLDS, BIOREACTORS AND GROWTH 
FACTORS 
  The use of scaffolds remains an integral part of the tissue 
engineering applications in orthopaedics and musculoskeletal 
sciences. We provide a summary of the principals of using 
material scaffolds in musculoskeletal tissue engineering 
applications and how these materials may eventually come to 
be incorporated in clinical practice. This is followed by a 
review of bioreactors that engineered tissue can be generated 
in. We discuss the role of bioreactors in tissue engineering 
and evaluate the principles of bioreactor design. We evaluate 
the methods of cell stimulation and review the bioreactors in 
common use today. Research has shown the importance of 
growth factors in guiding and modulating the differentiation 
of mesenchymal stem cells in order to obtain the required 
cell type. Gene-based delivery systems have aided the 
delivery of sustained quantities of these growth factors. The 
evidence from growth factor enhanced tissue engineering 
studies for tissue healing looks very positive. This is a multi-
disciplinary approach that integrates molecular, biochemical 
and clinical techniques with developmental and engineering 
processes. Initial studies indicate an immense potential for 
cell based strategies to enhance current orthopaedic 
approaches in skeletal tissue reconstruction and this is also 
covered in a review. 
E-GOVERNANCE 
  The rules of governance are changing. They are 
necessarily becoming more stringent as interventions offered 
to treat conditions carry unpredictable side effects, often 
associated with novel therapeutic vectors. The clinical 
relevance of this relates to the obligations of those involved 
in research, to ensure the best protection for subjects whilst 
encouraging the development of the field. Existing evidence 
supports the concept of e-Governance both in operational 
health research and more broadly in the strategic domain of 
policy formation. Building on the impact of the UK 
Comprehensive Research Network and recent EU Directives, 
it is now possible to focus on the issues of regulation for cell 
therapies in musculoskeletal science through the 
development of the Advanced Therapeutic Medicinal 
Products (ATMP) category of research products. We provide 
a review that covers the framework that has borne this and 
the need for more detailed Virtual Research Integration and 
Collaboration (VRIC) systems to ensure regulatory 
compliance. Technology research and development plans 
must develop in close association between tissue engineering 
and treating clinicians. The scope of this strategy relates to 
the handling of human tissues the transport and storage of 
specimens in accordance with current EU directives and the 
Human Tissue Authority (HTA) regulations. 
DUPUYTREN’S DISEASE 
  Dupuytren’s disease is the most common condition seen 
by hand surgeons. It is not only prevalent but can also be a 
most debilitating condition resulting in significant loss of 
function of the fingers involved. The cause of this disease, 
however still remains largely unknown although some recent 
evidence suggests a stem cell etiology. We provide a review 
article that summarizes the current known knowledge of 
Dupuytren’s as well as the clinical findings, investigations, 
treatments available and looks at preliminary evidence of 
stem cell etiology. 
BONE 
  Tissue engineering of bone has the potential to overcome 
the limitations of using autologous, allogeneic or synthetic 
bone grafts to treat extensive bone defects and fracture non-
unions [26]. Over a million patients are treated annually to 
manage and regenerate bone tissue in sites of congenital 
defects, tumor resection or fractured bones [27]. This 
regeneration process is very complex and requires a 
morphogenetic signal, responsive host cells and a suitable 
scaffold [28]. An increasing variety of synthetic scaffolds for 
bone regeneration has become commercially available over 
the last century [27] that aim to provide a three dimensional 
substrate for cells to populate on and function appropriately. 
They should have appropriate mechanical properties, 
biocompatibility and biodegradability at a rate commensurate 
with remodelling [29]. 
  Stem cells have shown to be excellent carriers for gene 
transfer having the capability to be transduced. Gene transfer 
could enable growth factors and bone morphogentic proteins 
to enhance bone repair. Stem cells are implanted onto 
scaffolds, which are structures capable of supporting tissue 
formation by allowing cell migration, proliferation and 
differentiation. Research aims to produce scaffolds that 
deliver and retain cells, allow for cell attachment has 
adequate biodegradability, biocompatibility and non-
immunogenicity. However, having tried and testing 
numerous materials including synthetic and natural products 
research into the perfect scaffold product continues. We 
provide a review that aims to explain how stem cells were 
discovered, the techniques used to isolate stem cells, identify 
and manipulate them down different cell lineages and 
discuss the research into using stem cells to reconstruct bone 
using genetic modification and scaffolds. 
CARTILAGE 
  Osteoarthritis is the most prevalent disorder of the 
musculoskeletal system [30] and the frequent outcome for 
arthritis in large joints such as the knee is surgical 
intervention for joint replacement. A joint replacement tends 
to be successful in older sedentary patients but the limited 
lifetime of prostheses makes it much less desirable for 
younger and more active patients [31]. The numbers of 
primary and revision total knee replacements are projected to 
increase six-fold by 2030 [32] and this is the driving force 
behind numerous ongoing efforts to develop new cell-based 
strategies for the treatment of focal cartilage defects to 
prevent secondary osteoarthritis [2]. Current options for the 
repair of focal cartilage lesions include abrasive 
chondroplasty, subchondral drilling and microfracture. These 
result in the formation of fibrocartilage rather than the 
desired hyaline cartilage, with inferior mechanical and 
hydroelastic characteristics [33]. Autologous Chondrocyte 
Implantation is a cell-based strategy currently in clinical 
practice [34, 35]. Although short-term clinical results have 
been good, evidence suggests formation of fibrocartilage and 
progression of degenerative changes in the joint [36]. Editorial  The Open Orthopaedics Journal, 2011, Volume 5    241 
  Tissue engineering applications using mesenchymal stem 
cells present an interesting new approach for the repair of 
articular cartilage defects [2,37]. To date there have been 
only limited reports of human autologous bone marrow 
derived cell implantation for cartilage repair [38-40]. We 
include a review that looks at the current treatment strategies 
for articular cartilage, describes use of mesenchymal stem 
cells for articular cartilage repair along with the results of 
clinical studies, and describes the future direction that these 
strategies are likely to take. 
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